The European Patent Office (EPO) has granted a new CRISPR/Cas9 patent (EP 4 289 948) to Professor Charpentier, along with The Regents of the University of California and the University of Vienna (collectively known as CVC). The divisional patent includes broad independent claims covering single guide RNAs,… Read More
bit.bio has successfully defended its foundational European patent for opti-ox, a technology the company says enables deterministic forward programming of pluripotent stem cells (PSCs). Following an anonymous opposition filed on 5 January 2023 and a public hearing on 25 September 2024, the European Patent Office’s (EPO)… Read More
The European Patent Office (EPO) has granted a licensed patent to ONK Therapeutics covering CISH knockout (KO) in natural killer (NK) cells, irrespective of the source of the NK cells. The patent includes human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem… Read More
